FORMULATION, OPTIMIZATION AND DEVELOPMENT OF ALBENDAZOLE TABLET FOR THE IMPROVEMENT OF ORAL BIOAVAILABILITY
*Hanmant B. Salunkhe, Karmude K. T., Gurav Y. A. and Sandeep Walasangikar
ABSTRACT
Albendazole is a benzimidazole carbamate with a broad anti-parasitic
spectrum. Albendazole was first approved for treatment of helminth
infections in sheep in 1977, and subsequently approved for human use
in 1983. In general, most ascariasis, trichuriasis, enterobiasis and
hookworm infections can be successfully treated with single dose
Albendazole and strongyloidiasis with multiple doses of Albendazole.
The increase in bioavailability is possible by in vitro drug dissolution
method. The physicochemical property of most drugs that has greatest
influence on their absorption characteristics from the GIT is
dissolution rate. The in vivo test is extremely costly, tedious, time
consuming besides exposing the healthy subject to hazards of drug. The in vitro method is
inexpensive. The best available tool today which can at least quantitatively assure about the
biological availability of a drug from its formulation is its in vitro dissolution test.
Enhancement of bioavailability of hydrophobic drugs is one of the major challenges in drug
development of the plethora of pharmaceutical technologies available to address this issue
viz. micronization, the use of surfactants.
Keywords: Micronization, Surfactant, superdisintegrants.
[Full Text Article]